Kornimate/medical-research-clean huggingface dataset:
multicentric cohort of melanoma patients in ile de france area

Conditions: Melanoma; Genetic Polymorphism

Summary: this is a multicentric prospective cohort of all stage melanoma patients from ap-hp ,the largest consortium of university hospitals over europe. 7 investigation sites (7 dermatological services of ap-hp) in ile de france region are involved. 1300 patients will be enrolled and be followed during 10 years.

melan-cohort should constitute the first multicentric cohort with various objectives: prognostic, therapeutic, cognitive and medico-economical studies on melanoma. patients will be recruited in all of the dermatology departments of aphp (dermatology departments from ambroise pare, saint-louis, bichat-claude bernard,henri-mondor, cochin-tarnier, and tenon hospitals). for all included patients, a standard file is filled comprising all anatomy-clinical useful data and epidemiologic ones, including sun exposures. blood is harvested to collect dna, rna, serum, plasma at inclusion and at regular intervals and in case of progressive disease. procedures for sentinel lymph node biopsies have been homogenized. an informed consent is obtained for each patient included in the cohort. a steering committee meets on a regular basis, and genetics or pathology subgroups have been constituted. an electronic crf is available using the intranet of aphp hospitals. specimens are stored using high quality standards.

Eligibility criteria:
inclusion criteria : * age ≥ 18 years * an informed consent is obtained * patients with anatomy-pathologically proved melanoma * the tissue sample of melanoma is available * the primary melanoma is treated according to the international standard * absence of a progressive non neoplastic pathology involving life-threatening * patient living in ile de france region. * time limit to entry in the cohort must be: * within 3 months after surgical resumption of primary melanoma; * within 3 months after curative surgical treatment; * with one month after diagnosis of a transit metastasis or a distant metastasis. exclusion criteria : * refusal of the patient * pathology sample isn't available * primary melanoma not being treated according to the international standard * patient living too far to follow regular visits * patient diagnosed with a progressive non neoplastic pathology involving life-threatening * too late to entry and lack of useful stored specimens to research.

Keywords: skin cancer melanoma sentinel lymph node biopsy bio bank genetic polymorphism prospective cohort cohort sentinel lymph nodes tissue samples
the development of incisional hernia in relation to specimen extraction site after laparoscopic colorectal surgeries

Conditions: Hernia

Summary: this is a retrospec/ve cohort study of colon cancer patients who underwent laparoscopic colorectal surgeries at prince sultan military medical city (psmmc) in riyadh, saudi arabia. the aim of this study is to determine the best site for specimen extrac/on with lowest risk of developing incisional hernia a0er laparoscopic colorectal surgeries.


Eligibility criteria:
inclusion criteria: * the study included all colorectal cancer patients over 2 years who were followed up or admitted to psmmc under the service of colorectal surgery unit and who underwent laparoscopic low anterior resection, left colectomy or right colectomy with an age of 16 years or older. exclusion criteria: * duplicated data, subjects younger than 16, patients with previous abdominal surgery, and surgically complicated cases which were converted to open surgery were excluded.
yoga for adolescent idiopathic scoliosis (ais) patients

Conditions: Adolescent Idiopathic Scoliosis; Spinal Fusion

Summary: adolescent idiopathic scoliosis (ais) is defined as a three-dimensional lateral deformity of the spine. it is described with a cobb angle of greater than 10 degrees. there is no known etiology of ais. once the degrees of curvature become severe (greater than 45 degrees), surgical intervention (posterior spinal fusion - psf) is often discussed. most adolescent patients and their families opt for surgical correction to decrease future complications of severe scoliosis, such as decreased vital capacity of the lungs, potential future activity restrictions, cosmetic appearance, and self-esteem. while the patient and family are eager to undergo psf, they do have concerns. the major concerns are pain control and their ability to return to activities. in current literature, there are many studies completed regarding pharmacologic pain control management with the use of iv patient-controlled analgesia (pca) with opioids, narcotics, non-steroidal anti-inflammatories, muscle relaxers, tylenol, and gabapentin. however, there is not a well-established multimodal pain management plan for postoperative psf patients. there is also no current literature discussing nonpharmacologic pain management methods, such as stretching, strengthening and yoga, for patients undergoing psf. there are multiple studies discussing core stabilization used for helping ais patients non-operatively. there is no literature discussing the use of nonpharmacologic pain management methods for improved pain control (including decreased use of pharmacologic agents) and quicker return to activities. the aim of this study is to determine if patients with ais undergoing psf require fewer pain medications and have an earlier return to activities if completing a yoga program six weeks prior to their surgery.


Eligibility criteria:
inclusion criteria: * idiopathic scoliosis patients * english speaking patient and parents exclusion criteria: * non idiopathic scoliosis diagnosis * no access to internet or computer * non-english speaking parents and/or patient
primary ovarian insufficiency, polycystic ovary syndrome & the cardiovascular risk profile

Conditions: Cardiovascular Diseases

Summary: the polycystic ovary syndrome (pcos) is the most common endocrinopathy amongst women of reproductive age. pcos is associated with various cardiovascular risk factors such as obesity, glucose intolerance, dyslipidemia hypertension and the metabolic syndrome. whether these increased cardiovascular risk factors result in the development of actual cardiovascular disease in later life remains to be established. women with premature ovarian insufficiency (poi), experience menopause prior to the age of 40 years. women with poi may exhibit dyslipidemia. a young age at menopause has been previously associated with increased cardiovascular morbidity and mortality.

cardiovascular risk profile will be assessed in women with pcos and poi \> 45 years of age, consisting of: fasting serum and urine analyses blood pressure, length, weight, waist circumference, hip circumference ecg carotid intima media thickness cardiac ultrasound spare serum, plasma and urine will be stored in -80 degrees celsius biobank.

Eligibility criteria:
inclusion criteria: * age above 45 years exclusion criteria: * none
mri-guided cryoablation to alleviate pain in head, neck and spine

Conditions: Facet Joints; Degeneration; Neuropathy; Neuralgia

Summary: the objective of this study is to provide pain relief to patients with facet joint disease or head and neck pain related to compression of a nerve root. the goal is to provide palliative care with superior efficacy and longer relief compared to current methods.

nerve ablation is used therapeutically to produce temporary anesthesia and diagnostically to locate the source of pain. ablation, or purposeful destruction of tissue, relieves facet joint pain and pain related to nerve damage by disabling pain-transmitting nerves. cryoablation for pain management is particularly useful when other modalities are too difficult to perform or have a high incidence for complications or side effects. currently nerve ablation is performed with bupivacaine and alcohol, but mri-guided cryoablation of nerves and facets may result in superior efficacy and longer relief. cryotherapy techniques provide long term analgesia and help alleviate intractable pain for patients with facet joint pain and neuralgia. minimally invasive magnetic resonance (mr)-guided ablation of nerves and facets may lead to decreased procedure time and increased relief of pain due to cancer or nerve degeneration. with the advent of the advanced multimodality image guided operating suite (amigo) at the brigham and women's hospital, we have exceptional capabilities for minimally invasive image-guided procedures, including different ablation techniques. the amigo suite is equipped with hardware that will keep the patient stationary while the magnetic resonance imaging scanner moves to the patient. additionally, the monitoring software within the amigo suite allows clinicians to instantaneously analyze the imaging information which significantly reduces the risk of injury to adjacent structures.

Eligibility criteria:
inclusion criteria: * participants must be willing and able to sign a written informed consent document. * patients must have facet joint disease or pain due to a damaged or compressed nerve that would benefit from a minimally invasive image-guided procedure (i.e., adjacent to critical structures, better visualized under 3 tesla mri than ct) * subjects must be able to adhere to the visit schedules and attend pre and post imaging. * participants must be at least 18 years of age * participants must have an estimated life expectancy of \>8 weeks in the opinion of the clinician. * patients with radiculopathy must have the cause of pain confirmed by a nerve block within 3 months prior to ablation exclusion criteria: * contraindications to mri and gadolinium- (i.e. estimated glomerular filtration rate \<60ml/min, metal clips) * pregnant or breastfeeding woman are excluded from this research.

Keywords: cryoablation nerves facet joint pain neuralgia neuropathy image-guided
efficacy study of two silicon-based products to treat scars

Conditions: Scars

Summary: this study aims to determine if a silicon-based gel and a silicon-based aerosol are effective in the treatment of postoperative scars.

improve the final aspect of scars, have been a challenge for medicine. silicon based products have been used in various ways to prevent hypertrophic scars and keloids since 1980. a great percentage of studies shows that silicon-based products improves the aspect of scars in different pathologies. the main objective of this trial is to evaluate the efficacy, using the vancouver scale, of two silicon-based products (kelofin gel and kelofin aerosol) after 180 days. 300 participants that meet all the inclusion criteria and are not classified in any of the exclusion criteria will be randomly allocated to one of thre treatment groups( kelofin gel, kelofin aerosol and no treatment) of the study.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin phototype i, ii, iii or iv * participant that has a recent surgical scar on remodeling phase (14 ± 7 days after surgery) from the following: breast plastic with inframammary incision (fold beneath the breast) or abdominoplasty, cesarean section, hysterectomy (removal of the uterus), oophorectomy (removal of ovaries), oophoroplasty (removal of nodules, cysts, etc. of the ovaries), salpingectomy (removal of the fallopian tubes), tubal ligation, exploratory laparotomy and ectopic pregnancy (pregnancy outside the uterus) (pfannenstiel access road - transverse incision , below the navel and approximately one finger above the symphysis pubis). exclusion criteria: * skin pathology in the product application area; * diabetes; * immune impairment; * use of systemic corticosteroids or immunosuppressants; * skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis; * background reaction to silicon-based products; * other illnesses or medications that may interfere directly in the study or endanger the health of the participant.

Keywords: postoperative scars cicatrix cicatrization
methadone levels in breast milk of women taking methadone for opiate addiction - 2

Conditions: Breast Feeding; Opioid-Related Disorders

Summary: methadone is a drug that offers significant therapeutic benefits to opiate dependent women who are pregnant. currently, it is the treatment of choice for this group of people. the purpose of this study is to determine the amount of methadone in the breast milk of women who are breastfeeding and taking methadone for opiate addiction. in addition, this study will evaluate the effects of methadone on infant neurobehavior.

methadone is a drug that is commonly used to treat opiate addiction, usually as part of a detoxification and maintenance program. methadone offers significant therapeutic benefits to pregnant women who are opiate dependent, and it is currently the treatment of choice for this group of people. in general, breast milk is beneficial for infants. however, there is some concern as to whether it is safe for women who are taking methadone to breastfeed their babies. the purpose of this study is to determine the amount of methadone in the breast milk of women who are breastfeeding and taking methadone for opiate addiction. in addition, this study will evaluate the effects of methadone on infant neurobehavior. participants will be assigned to one of two groups: women taking methadone who will breastfeed their babies or women taking methadone who will bottle-feed their babies. on days 1, 2, 3, 4, 14, and 30, following infant delivery, plasma will be collected from both groups and breast milk will be collected from the breastfeeding group. these samples will be quantitatively analyzed for methadone. infants will undergo neurobehavioral assessments on days 3, 14, and 30, following birth. rates and severity of neonatal abstinence syndrome will also be evaluated.

Eligibility criteria:
inclusion criteria: * generally healthy methadone-maintained women electing to either exclusively breastfeed or bottle-feed their infants for 1 month after delivery exclusion criteria: * relapse to illicit drugs or alcohol at any time during the study * positive maternal or infant urine toxicology test at birth * serious medical or psychiatric illness requiring medication or medical intervention * hiv infected * currently dependent on alcohol * major birth defect in the infant * significant medical problems in the infant, including premature birth, sepsis, or other infections

Keywords: methadone lactation breastfeeding maternal opioid dependency
study of the efficacy of maintenance therapy using uracil-tegafur (uft) or bacille calmette-guerin (bcg) for the prevention of recurrences of superficial bladder cancer (embark study)

Conditions: Bladder Cancer

Summary: the purpose of this prospective randomized controlled study is to prove the non-inferiority of uft maintenance therapy to bcg maintenance therapy for preventing recurrences of superficial bladder cancer.

patients who have undergone transurethral resection of a superficial bladder tumor (tur-bt) and bcg induction therapy are eligible for enrollment in this study. in principle, bcg induction therapy consists of the successive weekly intravesical administration of 81 mg of bcg-connaught strain or 80 mg of bcg-japan strain for 6 weeks after the completion of tur-bt. the patients will be randomly assigned to a bcg maintenance therapy arm or a uft maintenance therapy arm. the patients in the bcg maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of bcg at 3, 6, 12 and 18 months after the start of bcg induction therapy. the dosage of bcg used for bcg maintenance therapy will be the same as that used for bcg induction therapy. patients in the uft maintenance therapy arm will be treated with the oral administration of 400 mg of uft everyday for three years after the end of bcg induction therapy. the primary endpoint of this study is the three-year relapse-free survival rate.

Eligibility criteria:
inclusion criteria: * superficial bladder cancer * completion of transurethral resection of bladder tumor (tur-bt) * completion of bcg induction therapy after tur-bt. in principle, bcg induction therapy consists of the successive weekly intravesical administration of 81 mg of bcg-connaught strain or 80 mg of bcg-japan strain for 6 weeks after the completion of tur-bt. * age 20 to 80 years * ecog performance status of 0 or 1 * bladder capacity ≥ 150 ml * capable of oral uft administration * expected life prognosis ≥ 3 years * hematopoietic wbc ≥ 3,000/mm\^3 * neutrophil ≥ 1,500/mm\^3 * platelet ≥ 100,000/mm\^3 * hepatic ast and alt ≤ 2 times upper limit of normal (uln) * total bilirubin ≤ 1.5 mg/dl * hemoglobin ≤ 9.0 g/dl * creatinine ≤ 1.5 mg/dl exclusion criteria: * bladder cancer located in prostatic part of the urethra * anamnesis of bladder cancer classified as ct2, ct3 or ct4 * anamnesis of metastatic bladder cancer * anamnesis of upper urinary tract carcinoma in situ * anamnestic treatment of intravesical bcg administration within previous 6 months * prior anticancer chemotherapy or radiotherapy * severe complication * presence of contraindications for the administration of bcg or uft * pregnancy, lactation

Keywords: uft bcg
comparing acupuncture, biomodulator, and transcutaneous electrical nerve stimulation for symptomatic treatment of chronic pain.

Conditions: Chronic Pain; Depression; PTSD Symptoms; Sleep

Summary: the primary objective of this preliminary study is to compare the tennant biomodulator with transcutaneous electrical nerve stimulation (tens) and traditional chinese acupuncture for the management of chronic pain among injured service members. the secondary objective is to investigate any associative effects or benefits on sleep, post-traumatic stress disorder (ptsd) symptoms, or depression.


Eligibility criteria:
inclusion criteria: * subjects must be injured service members between the ages of 18 and 60, inclusive; * the pain must have been present for 3 months or greater prior to entry into the study; * subjects must agree to follow the medication regime as directed by the pain clinic provider for the duration of the study; * subjects must be able to speak and read english and understand study procedures exclusion criteria: * epilepsy * pregnancy, or considering pregnancy within the study time-frame * pacemaker * history of cardiac arrhythmias * implantable devices (aicd, pump, etc.) * surgical intervention during the past month for the treatment of low back pain or its underlying etiology * documented history of prescription medication abuse * abuse of illicit drugs within the last 6 months * participation in a clinical trial for an investigational drug and/or agent within 30 days prior to screening
am-101 in the treatment of post-acute tinnitus 1

Conditions: Tinnitus

Summary: the purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of am-101.

this open-label extension study is assessing the safety and local tolerance of repeated treatment cycles of am-101 in subjects previously treated in the scope of the tactt2 study (nct01803646).

Eligibility criteria:
inclusion criteria: * completion of tactt2 study; * negative pregnancy test (woman of childbearing potential); * willing and able to attend the study visits during at least one treatment cycle. other protocol-defined inclusion criteria may apply. exclusion criteria: * adverse event leading to treatment discontinuation in tactt2; * meniere's disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating hearing loss, otitis media, otitis externa, abnormality of tympanic membrane; * ongoing drug-based therapy for otitis media or otitis externa; * drug-based therapy known as potentially tinnitus-inducing; * other treatment of tinnitus; * drug abuse or alcoholism; * subjects with psychiatric diseases requiring drug treatment; * use of antidepressant or anti-anxiety medication; * any clinically relevant disorder or abnormality in physical examination; * women who are breast-feeding, pregnant or who are planning to become pregnant during the study; * women of childbearing potential who are unwilling or unable to practice contraception. other protocol-defined exclusion criteria may apply.
the effect of hibiscus sabdariffa l. tea on blood pressure

Conditions: Hypertension

Summary: the goal of this study is to find out whether the plant compounds present in hibiscus sabdariffa, a plant commonly used in herbal tea blends and other beverages, will have a beneficial effect on blood pressure in people with mildly elevated blood pressure.


Eligibility criteria:
inclusion criteria: * systolic blood pressure 120-150 mm hg * diastolic blood pressure 95 mm hg or less * body mass index (bmi) 18.5-34.9 kg/m2 exclusion criteria: * smoking * use of medications that influence blood pressure * cardiovascular disease * chronic kidney disease * diabetes * regular use of vitamin c supplements (min 500 mg/day) within prior 30 days * regular strenuous aerobic activity greater than 30 min/day * excessive intake of caffeine or alcohol * pregnancy within last 6 months or during study period * abnormal complete blood count (cbc), urinalysis or electrocardiogram (ekg)

Keywords: pre-hypertension mild hypertension